A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia

AbbVie

Description

The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.

Citations (0)

No citations found

It looks like this dataset has no citations.

Mentions (0)

No mentions found

It looks like this dataset has not been mentioned in any sources.

Metrics

Dataset Index

0.8

FAIR Score

31%

Citations

Mentions

Metrics Over Time

Publication Details

DOI

10.25934/00002992

Publisher

Vivli

Assigned Domain

Subfield

Hematology

Field

Medicine

Domain

Health Sciences

Confidence Score

46%

Source

Scholar Data Model

Keywords

Conditions: DyslipidemiaConditions: Coronary Heart DiseaseConditions: Mixed DyslipidemiaInterventions: ABT-335 and rosuvastatin calciumInterventions: ABT-335 and atorvastatin calciumInterventions: ABT-335 and simvastatin

Normalization Factors

13.46

CTw

1.00

MTw

1.00